Other languages CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Real-time Estimate Cboe BZX Other stock markets 11:58:47 2024-06-26 EDT			5-day change	1st Jan Change
1.175 ^USD	-2.89%		-8.59%	-24.52%

06-17	CytomX Therapeutics, Inc. Promotes Chris Ogden to Chief Financial Officer	CI
05-28	Piper Sandler Upgrades CytomX Therapeutics to Overweight From Neutral, Adjusts Price Target to $3.50 From $2.25	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)	05-08
CytomX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08
CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab)	05-07
CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors	04-08
CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors	03-21
CytomX Therapeutics, Inc. Announces Milestone Achievement in Prospective T-Cell Engaging Bispecific Collaboration with Astellas	03-18
CytomX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11
CytomX Therapeutics, Inc. Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b	01-24
CytomX Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07
CytomX Therapeutics, Inc. Presents Preclinical Profile of EpCAM-Directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference	23-10-18
CytomX Therapeutics, Inc. Enters into a Transition Agreement with AbbVie Global Enterprises Ltd	23-08-24
Exelixis Appoints Amy Peterson as Chief Medical Officer	23-08-23
CytomX Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
CytomX Therapeutics, Inc. Appoints Yu-Waye Chu as Chief Medical Officer	23-07-18
CytomX Therapeutics Signs $30 Million Private Placement Deal with BVF Partners; Shares Rise	23-06-30
CytomX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09
CytomX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27
CytomX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27
CytomX Therapeutics Achieves First Clinical Candidate Milestone in Cancer Collaboration With Astellas; Shares Rise	23-01-26
CytomX Therapeutics, Inc. Announces Milestone Achievement in Probody T-Cell Engaging Bispecific Collaboration with Astellas	23-01-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Other languages

Filters